These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 18033059)

  • 1. [Science, marketing and pharmacovigilance: the example of topical calcineurin inhibitors].
    Paul C
    Ann Dermatol Venereol; 2007 Nov; 134(11):817-21. PubMed ID: 18033059
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence.
    Spergel JM; Leung DY
    Curr Allergy Asthma Rep; 2006 Jul; 6(4):270-4. PubMed ID: 16822378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?
    Ormerod AD
    Br J Dermatol; 2005 Oct; 153(4):701-5. PubMed ID: 16181449
    [No Abstract]   [Full Text] [Related]  

  • 4. Topical calcineurin inhibitors for atopic dermatitis: balancing clinical benefit and possible risks.
    Qureshi AA; Fischer MA
    Arch Dermatol; 2006 May; 142(5):633-7. PubMed ID: 16702502
    [No Abstract]   [Full Text] [Related]  

  • 5. Topical calcineurin inhibitors revisited.
    Qureshi A; Fischer MA
    Arch Dermatol; 2007 Apr; 143(4):545-6. PubMed ID: 17438195
    [No Abstract]   [Full Text] [Related]  

  • 6. Calcineurin inhibitors in pediatric atopic dermatitis: a review of current evidence.
    Kalavala M; Dohil MA
    Am J Clin Dermatol; 2011 Feb; 12(1):15-24. PubMed ID: 21067248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical calcineurin inhibitors labeling: putting the "box" in perspective.
    Stern RS
    Arch Dermatol; 2006 Sep; 142(9):1233-5. PubMed ID: 16983018
    [No Abstract]   [Full Text] [Related]  

  • 8. Update of calcineurin inhibitors to treat inverse psoriasis: A systematic review.
    Dattola A; Silvestri M; Bennardo L; Del Duca E; Longo C; Bianchi L; Nisticò S
    Dermatol Ther; 2018 Nov; 31(6):e12728. PubMed ID: 30295379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Topical calcineurin inhibitors in atopic eczema -- contra].
    Abeck D
    Dtsch Med Wochenschr; 2006 Jul; 131(28-29):1615. PubMed ID: 16823714
    [No Abstract]   [Full Text] [Related]  

  • 10. Malignancies and ustekinumab: an analysis of the U.S. Food and Drug Administration Adverse Event Reporting System and the European Union Drug Regulating Authorities Pharmacovigilance database.
    Florek AG; Nardone B; Thareja S; Tran G; Giles FJ; West DP
    Br J Dermatol; 2017 Nov; 177(5):e220-e221. PubMed ID: 28646575
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.
    Munzenberger PJ; Montejo JM
    Pharmacotherapy; 2007 Jul; 27(7):1020-8. PubMed ID: 17594208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current aspects of the therapy with topical calcineurin inhibitors].
    Enderlein E; Meller S; Rieker J; Ruzicka T; Homey B
    Hautarzt; 2005 Oct; 56(10):937-41. PubMed ID: 16142499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Topical immunomodulators, such as tacrolimus and pimecrolimus, in the treatment of atopic dermatitis].
    van der Laan JR
    Ned Tijdschr Geneeskd; 2005 Aug; 149(32):1816; author reply 1817. PubMed ID: 16121669
    [No Abstract]   [Full Text] [Related]  

  • 14. Facial flush reaction after alcohol ingestion during topical pimecrolimus and tacrolimus treatment.
    Stinco G; Piccirillo F; Sallustio M; Patrone P
    Dermatology; 2009; 218(1):71-2. PubMed ID: 18832812
    [No Abstract]   [Full Text] [Related]  

  • 15. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force.
    Berger TG; Duvic M; Van Voorhees AS; VanBeek MJ; Frieden IJ;
    J Am Acad Dermatol; 2006 May; 54(5):818-23. PubMed ID: 16635663
    [No Abstract]   [Full Text] [Related]  

  • 16. Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology.
    Fonacier L; Spergel J; Charlesworth EN; Weldon D; Beltrani V; Bernhisel-Broadbent J; Boguniewicz M; Leung DY; ;
    J Allergy Clin Immunol; 2005 Jun; 115(6):1249-53. PubMed ID: 15940142
    [No Abstract]   [Full Text] [Related]  

  • 17. The topical calcineurin inhibitor pimecrolimus in atopic dermatitis: a safety update.
    Thaçi D; Salgo R
    Acta Dermatovenerol Alp Pannonica Adriat; 2007 Jun; 16(2):58, 60-62. PubMed ID: 17992459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance.
    Langley RG; Luger TA; Cork MJ; Schneider D; Paul C
    Dermatology; 2007; 215 Suppl 1():27-44. PubMed ID: 18174691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ethanol-induced flushing with topical pimecrolimus use.
    Ogunleye T; James WD
    Dermatitis; 2008; 19(2):E1-2. PubMed ID: 18413100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between exposure to topical tacrolimus or pimecrolimus and cancers.
    Hui RL; Lide W; Chan J; Schottinger J; Yoshinaga M; Millares M
    Ann Pharmacother; 2009 Dec; 43(12):1956-63. PubMed ID: 19903860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.